Show simple item record

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

dc.contributor.authorSeddon, B
dc.contributor.authorStrauss, S
dc.contributor.authorWhelan, J
dc.contributor.authorLeahy, Michael G
dc.contributor.authorWoll, P
dc.contributor.authorCowie, F
dc.contributor.authorRothermundt, C
dc.contributor.authorWood, Z
dc.contributor.authorBenson, C
dc.contributor.authorAli, N
dc.contributor.authorMarples, M
dc.contributor.authorVeal, G
dc.contributor.authorJamieson, D
dc.contributor.authorKüver, K
dc.contributor.authorTirabosco, R
dc.contributor.authorForsyth, S
dc.contributor.authorNash, S
dc.contributor.authorDehbi, H
dc.contributor.authorBeare, S
dc.date.accessioned2017-10-23T19:47:39Z
dc.date.available2017-10-23T19:47:39Z
dc.date.issued2017-10
dc.identifier.citationGemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. 2017, 18 (10):1397-1410 Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid28882536
dc.identifier.doi10.1016/S1470-2045(17)30622-8
dc.identifier.urihttp://hdl.handle.net/10541/620621
dc.description.abstractFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.subject.meshAdult
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshConfidence Intervals
dc.subject.meshDeoxycytidine
dc.subject.meshDisease-Free Survival
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshDoxorubicin
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfusions, Intravenous
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Invasiveness
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Staging
dc.subject.meshPrognosis
dc.subject.meshSarcoma
dc.subject.meshSoft Tissue Neoplasms
dc.subject.meshSurvival Analysis
dc.subject.meshTaxoids
dc.subject.meshTreatment Outcome
dc.subject.meshUnited Kingdom
dc.titleGemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentUniversity College London Hospitals NHS Foundation Trust, London, UK.en
dc.identifier.journalThe Lancet Oncologyen
refterms.dateFOA2018-12-17T15:05:25Z
html.description.abstractFor many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced or metastatic soft-tissue sarcoma.


Files in this item

Thumbnail
Name:
PIIS1470204517306228.pdf
Size:
510.2Kb
Format:
PDF
Description:
Full text, Open Access article
Download

This item appears in the following Collection(s)

Show simple item record